Asset profile
Capmatinib
Small molecule
Evidence outlook
Accelerated approval: Non-Small Cell Lung Cancer (label: metastatic NSCLC with MET exon 14 skipping mutation)
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
73 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Capmatinib: this drug | Approved | Small molecule | MET | ||
| Telisotuzumab Vedotin | Approved | Antibody–drug conjugate | MET | ||
| Tepotinib (Tepmetko) | Approved | Small molecule | MET | ||
| ASKC202 | Phase 3 | Small molecule | MET | ||
| Glumetinib | Phase 3 | Small molecule | MET | ||
| Savolitinib (Orpathys) | Phase 3 | Small molecule | MET | ||
| Telisotuzumab Adizutecan | Phase 3 | Antibody–drug conjugate | MET | ||
| Vebreltinib | Phase 3 | Small molecule | MET | ||
| ABBV-400 | Phase 2 | Antibody–drug conjugate | MET | ||
| RC108 | Phase 2 | Antibody–drug conjugate | MET | ||
| CKD-703 | Phase 1/2 | Antibody–drug conjugate | MET | ||
| REGN5093 | Phase 1/2 | Monoclonal antibody | MET | ||
| VERT-002 | Phase 1/2 | Monoclonal antibody | MET | ||
| DO-2 | Phase 1 | Small molecule | MET | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK |
…and 58 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
7 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (3)
April 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
2029 (2)
October 2029 (2)
What to watch
What to watch
2031 (1)
February 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.